Neurosyphilis

Summary

Neurosyphilis (MONDO:0004944) is a disease and 5 clinical trials. Top therapeutic interventions include ceftriaxone sodium and penicillin g potassium. A subtype of tertiary syphilis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neurosyphilis
Mondo ID	MONDO:0004944
MeSH	D009494
DOID	DOID:9988
ICD-10-CM	A52.3
ICD-11	2118246468
NCIT	C84935
SNOMED CT	26039008
UMLS	C0027927
MedGen	14360
GARD	0008729
Is cancer (heuristic)	no

Also known as: neurosyphilis

Disease family

This is a subtype of tertiary syphilis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › syphilis › tertiary syphilis › neurosyphilis

Related subtypes (3): gummatous syphilis, cardiovascular syphilis, late latent syphilis

Subtypes (4): parenchymatous neurosyphilis, meningovascular neurosyphilis, asymptomatic neurosyphilis, tabes dorsalis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01589289	PHASE3	COMPLETED	Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
NCT03418441	Not specified	RECRUITING	Central Nervous System Infections in Denmark
NCT06680011	Not specified	RECRUITING	Cohort-Based Study of Diagnostic Biomarkers for Neurosyphilis
NCT00000648	Not specified	COMPLETED	A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals
NCT06152393	Not specified	COMPLETED	Value of an Intrathecal Synthesis Index of Specific Antitreponema IgG for Neurosyphilis Diagnosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CEFTRIAXONE SODIUM	4	1
PENICILLIN G POTASSIUM	4	1
CHEMBL4101392	0	1